AU2020205114A1 - Inhibitors of cGAS activity as therapeutic agents - Google Patents

Inhibitors of cGAS activity as therapeutic agents Download PDF

Info

Publication number
AU2020205114A1
AU2020205114A1 AU2020205114A AU2020205114A AU2020205114A1 AU 2020205114 A1 AU2020205114 A1 AU 2020205114A1 AU 2020205114 A AU2020205114 A AU 2020205114A AU 2020205114 A AU2020205114 A AU 2020205114A AU 2020205114 A1 AU2020205114 A1 AU 2020205114A1
Authority
AU
Australia
Prior art keywords
pyrimidin
compound
methylbenzofuro
carboxylic acid
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020205114A
Other languages
English (en)
Inventor
Matthew Boxer
Susan BOYD
Meera Kumar
Robert G. Lowery
David Maloney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BellBrook Labs LLC
Original Assignee
BellBrook Labs LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BellBrook Labs LLC filed Critical BellBrook Labs LLC
Publication of AU2020205114A1 publication Critical patent/AU2020205114A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2020205114A 2019-01-04 2020-01-03 Inhibitors of cGAS activity as therapeutic agents Abandoned AU2020205114A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962788624P 2019-01-04 2019-01-04
US62/788,624 2019-01-04
PCT/US2020/012243 WO2020142729A1 (en) 2019-01-04 2020-01-03 Inhibitors of cgas activity as therapeutic agents

Publications (1)

Publication Number Publication Date
AU2020205114A1 true AU2020205114A1 (en) 2021-07-22

Family

ID=72338800

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020205114A Abandoned AU2020205114A1 (en) 2019-01-04 2020-01-03 Inhibitors of cGAS activity as therapeutic agents

Country Status (8)

Country Link
US (1) US20220073532A1 (https=)
EP (1) EP3906241A4 (https=)
JP (1) JP7507161B2 (https=)
KR (1) KR20210112316A (https=)
CN (1) CN113302194A (https=)
AU (1) AU2020205114A1 (https=)
CA (1) CA3125625A1 (https=)
WO (1) WO2020142729A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021349249A1 (en) * 2020-09-24 2023-04-13 Ventus Therapeutics U.S., Inc. Pyrido(4,3-b)indole derivatives and their use as pharmaceuticals
US20240174684A1 (en) * 2021-02-11 2024-05-30 Bellbrook Labs, Llc INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS
CN117337291A (zh) * 2021-05-12 2024-01-02 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有C-连接环状取代基的吡啶衍生物
CN119119063A (zh) 2021-05-12 2024-12-13 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物
WO2022238335A1 (en) 2021-05-12 2022-11-17 Boehringer Ingelheim International Gmbh Pyridine derivatives with c-linked cyclic substituents as cgas inhibitors
JP2025528113A (ja) * 2022-08-10 2025-08-26 ベルブルック ラボズ，エルエルシー 治療剤としてのｃＧＡＳ活性の阻害剤
KR20250103719A (ko) 2022-11-09 2025-07-07 베링거 인겔하임 인터내셔날 게엠베하 cGAS 억제제로서의 사이클릭 벤즈이미다졸 유도체
AU2023376006A1 (en) * 2022-11-09 2025-03-13 Boehringer Ingelheim International Gmbh Cyclic pyridine derivatives as cgas inhibitors
WO2025172882A1 (en) 2024-02-14 2025-08-21 Janssen Pharmaceutica Nv Substituted pyrrolidine-2-carboxylic acid derivatives as cgas inhibitors
WO2025233174A1 (en) 2024-05-08 2025-11-13 Boehringer Ingelheim International Gmbh Benzimidazole derivatives as cgas inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755583A (en) * 1970-06-05 1973-08-28 Chas0!nhx
DE10348023A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
EP1812113A1 (en) * 2004-11-11 2007-08-01 Argenta Discovery Limited Pyrimidine compounds as histamine modulators
EP1767537A1 (en) * 2005-09-21 2007-03-28 Cellzome (UK) Ltd. Pyrimidine compounds for the treatment of inflammatory disorders
KR20090028819A (ko) * 2006-07-11 2009-03-19 얀센 파마슈티카 엔.브이. 히스타민 ｈ４ 수용체의 벤조푸로- 및 벤조티에노피리미딘 조절제
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2013115167A1 (ja) * 2012-01-31 2013-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 アムバチニブ誘導体
CN104513258B (zh) * 2013-09-26 2018-04-03 广东东阳光药业有限公司 取代脲衍生物及其在药物中的应用
KR20250065420A (ko) * 2015-12-25 2025-05-12 가부시키가이샤 한도오따이 에네루기 켄큐쇼 화합물, 발광 소자, 표시 장치, 전자 기기, 및 조명 장치
WO2019084271A1 (en) * 2017-10-25 2019-05-02 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHODS OF USE

Also Published As

Publication number Publication date
US20220073532A1 (en) 2022-03-10
EP3906241A1 (en) 2021-11-10
EP3906241A4 (en) 2022-11-02
WO2020142729A1 (en) 2020-07-09
KR20210112316A (ko) 2021-09-14
JP2022518148A (ja) 2022-03-14
CA3125625A1 (en) 2020-07-09
JP7507161B2 (ja) 2024-06-27
CN113302194A (zh) 2021-08-24

Similar Documents

Publication Publication Date Title
JP7507161B2 (ja) 治療薬としてのｃＧＡＳ活性の阻害剤
JP7507162B2 (ja) 治療薬としてのｃＧＡＳ活性の阻害剤
US8058446B2 (en) Certain substituted amides, method of making, and method of use thereof
TWI398439B (zh) 特定經取代醯胺、其製法及其用途
US20080153834A1 (en) Certain Substituted Amides, Method of Making, and Method of Use Thereof
NZ555681A (en) Imidazo[1, 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
JP2009539881A (ja) Ｄｐ−２アンタゴニストとしての置換フェニル酢酸
US20240174684A1 (en) INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS
TW202448435A (zh) 經取代之噻二唑基化合物
US12325701B2 (en) YKL-40 inhibitors and their therapeutic
TW201441193A (zh) 吡啶酮化合物
WO2024076677A2 (en) Imidazolyl-alkoxyquinolin-2-amines
WO2024035622A1 (en) INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS
WO2025255442A1 (en) Trim21-targeted compounds and uses thereof
CN121895236A (zh) 一种itk激酶选择性抑制剂及其应用

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application